Respiratory Diseases

 
Direct Mail to Older Adults at Risk for Pneumococcal Disease Improves Vaccination Rates
April 02, 2025

A mail campaign targeting adults with chronic conditions as well as their GPs increased the number receiving at least 1 shot by 9.5 percentage points.

Omlyclo Gains FDA Approval as Interchangeable Omalizumab Biosimilar: Daily Dose
March 24, 2025

Your daily dose of the clinical news you may have missed.

Dupilumab Found Beneficial in COPD with Type 2 Inflammation: Daily Dose
March 20, 2025

Your daily dose of the clinical news you may have missed.

FDA Approves Omlyclo as First Interchangeable Omalizumab Biosimilar
March 10, 2025

Omlyclo is indicated for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps, IgE-mediated food allergy, and chronic spontaneous urticaria.

Dupilumab Shows Efficacy and Safety in COPD With Type 2 Inflammation: AAAAI 2025
March 06, 2025

Investigators concluded that dupilumab reduced exacerbation rates, improved lung function, and decreased systemic corticosteroid use in patients with COPD driven by type 2 inflammation.

Depemokimab Shows Significant Improvements in Rhinosinusitis with Nasal Polyps: New Research
March 05, 2025

AAAAI 2025: Data from the ANCHOR-1 and ANCHOR-2 phase 3 trials show improvements in nasal polyp size and obstruction for depemokimab with twice-yearly dosing vs placebo.

With the Flu Season in Overdrive, Hospitals are Overwhelmed
February 12, 2025

Some hospitals have EDs filled with patients and a number of states are reporting the 2024-2025 version of a COVID-19, flu, and RSV tripledemic.

FDA Grants Priority Review to Brensocatib, First Targeted Treatment for Bronchiectasis
February 07, 2025

The FDA has set the Prescription Drug User Fee Act target action date for bronchiectasis for August 12, 2025, Insmed Incorporated announced.

Vaccine Hesitancy in the Chronic Conditions Community: New Survey Findings
January 24, 2025

People with chronic diseases like COPD or with immunocompromising conditions continue to have reservations about vaccines against flu, COVID-19, and RSV.

FDA Proposed Rule Would Limit Nicotine Content in Cigarettes, Cigars, Other Combusted Products
January 16, 2025

The agency estimates that limiting nicotine levels could lead to 1.8 million fewer tobacco-related deaths by 2060 and health care savings of $1.1 trillion a year over the next 40 years.